Marker Therapeutics (MRKR)
NASDAQ:MRKR
Want to see MRKR full AI Analyst Report?
Total Valuation
Marker Therapeutics has a market cap or net worth of $23.51M. The enterprise value is $525.25K.
Market Cap$23.51M
Enterprise Value$525.25K
Share Statistics
Marker Therapeutics has 16,673,126 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,673,126
Owned by Insiders18.09%
Owned by Institutions15.29%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is >-0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)>-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-2.43T
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is ―. Marker Therapeutics’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-3.49
PEG Ratio0.06
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 0.00 and earned -12.16M in profits. Earnings per share was -0.79.
Revenue0.00
Gross Profit0.00
Operating Income-12.89M
Pretax Income-12.18M
Net Income-12.16M
EBITDA-12.44M
Earnings Per Share (EPS)-0.79
Cash Flow
In the last 12 months, operating cash flow was -7.92M and capital expenditures -4.00, giving a free cash flow of -7.92M billion.
Operating Cash Flow-7.92M
Free Cash Flow-7.92M
Free Cash Flow per Share-0.47
Dividends & Yields
Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change26.55%
50-Day Moving Average1.44
200-Day Moving Average1.31
Relative Strength Index (RSI)47.20
Average Volume (3m)146.50K
Important Dates
Marker Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateMar 18, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Marker Therapeutics as a current ratio of 8.39, with Debt / Equity ratio of 0.00%
Current Ratio8.39
Quick Ratio8.39
Debt to Market Cap0.00
Net Debt to EBITDA1.29M
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Marker Therapeutics has paid -15.16K in taxes.
Income Tax-15.16K
Effective Tax Rate<0.01
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is 1.29M, with an EV/FCF ratio of 1.34.
EV to Sales0.00
EV to EBITDA1.29M
EV to Free Cash Flow1.34
EV to Operating Cash Flow1.34
Balance Sheet
Marker Therapeutics has $14.92M in cash and marketable securities with $0.00 in debt, giving a net cash position of $14.92M billion.
Cash & Marketable Securities$14.92M
Total Debt$0.00
Net Cash$14.92M
Net Cash Per Share$0.89
Tangible Book Value Per Share$1.10M
Margins
Gross margin is -99.47%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-99.47%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Marker Therapeutics is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.00
Price Target Upside442.17% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-43.86%
EPS Growth Forecast49.21%